LadRx (LADX) Debt-to-Equity : 0.32 (As of Dec. 2023)

View and export this data going back to 1986. Start your Free Trial

What is LadRx Debt-to-Equity?

LadRx's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.03 Mil. LadRx's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. LadRx's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $0.11 Mil. LadRx's debt to equity for the quarter that ended in Dec. 2023 was 0.32.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for LadRx's Debt-to-Equity or its related term are showing as below:

LADX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07 Med: 0.45 Max: 8.85
Current: 0.32

During the past 13 years, the highest Debt-to-Equity Ratio of LadRx was 8.85. The lowest was 0.07. And the median was 0.45.

LADX's Debt-to-Equity is ranked worse than
67.16% of 1072 companies
in the Biotechnology industry
Industry Median: 0.15 vs LADX: 0.32

LadRx Debt-to-Equity Historical Data

The historical data trend for LadRx's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LadRx Debt-to-Equity Chart

LadRx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.07

0.09

8.85

0.32

LadRx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															8.85	-0.16	0.08	0.09	0.32

Competitive Comparison of LadRx's Debt-to-Equity

For the Biotechnology subindustry, LadRx's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LadRx's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LadRx's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where LadRx's Debt-to-Equity falls into.

LadRx Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

LadRx's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.034	+	0)	/	0.107
	=	0.32

LadRx's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.034	+	0)	/	0.107
	=	0.32

LadRx (OTCPK:LADX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

LadRx Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of LadRx's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

LadRx (LADX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LadRx Corp (OTCPK:LADX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

11726 San Vicente Boulevard, Suite 650, Los Angeles, CA, USA, 90049

Website

https://www.ladrxcorp.com

LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.

Executives

Cary J Claiborne	director	3056 SENECA CHIEF TRAIL, ELLICOTT CITY MD 21042
Stephen Snowdy	officer: Chief Executive Officer	C/O CYTRX CORPORATION, 11726 SAN VICENTE BOULEVARD, SUITE 650, LOS ANGELES CA 90049
Jennifer K. Simpson	director	C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019
Eric Curtis	officer: Pres., Chief Operating Officer	ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Felix Kratz	officer: Vice President Drug Discovery	11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Joel K Caldwell	director	11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Chawla Shanta M.d.	officer: Senior VP-Drug Development	11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Earl W Brien	director	11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Olivia C Ware	officer: Chief Commercial Officer	11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Cheryl Cohen	director	C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Eric Jay Selter	director	11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Anita J Chawla	director	11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Joseph Rubinfeld	director	C/O SUPERGEN INC, 4140 DUBLIN BLVD STE 200, DUBLIN CA 94568
Douglas Scott Wieland	officer: Sr VP - Drug Development	11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Louis Ignarro	director	11726 SAN VICENTE BLVD, STE 650, LOS ANGELES CA 90049